stockportfolio.pro
Stocks / AVTX vs CRMD
AVTX vs CRMD
Avalo Therapeutics, Inc. and CorMedix Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Avalo Therapeutics, Inc. (AVTX) | CorMedix Inc. (CRMD) | |
|---|---|---|
| Market cap | $0.7B | $0.7B |
| Revenue (latest FY) | $59,000 | $311.71M |
| Net income (latest FY) | $-78.26M | $163.06M |
| Revenue growth (5y CAGR) | -61.2% | 319.7% |
| Net margin | -132642.4% | 52.3% |
| Return on equity | -94.2% | 40.2% |
| P/E ratio | — | 4.1 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 1 |
| Positive free cash flow | — | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AVTX — free Open CRMD — freeFrequently asked questions
Which is bigger, AVTX or CRMD?
Avalo Therapeutics, Inc. is larger by market capitalization — $0.7B versus $0.7B.
Which grows faster, AVTX or CRMD?
Over the last five fiscal years, CorMedix Inc. grew revenue faster — 319.7%/yr versus -61.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.